Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

PF-610355

From Wikipedia, the free encyclopedia
Respiratory medication
Pharmaceutical compound
PF-610355
Clinical data
Routes of
administration		Inhalation
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
  • N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2-{[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC34H39N3O6S
Molar mass617.76 g·mol−1

PF-610355 (also known asPF-00610355 orPF-610,355) is an inhalable[1]ultra-long-acting β2 adrenoreceptor agonist[2] (ultra-LABA) that was investigated as a treatment ofasthma andCOPD byPfizer.[3] It utilizes asulfonamideagonist headgroup, that confers high levels of intrinsiccrystallinity that could relate to the acidic sulfonamide motif supporting azwitterionic form in the solid state. Optimization ofpharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically mediatedadverse events.[4] Itsin vivo duration on action confirmed its potential for once-daily use in humans.[5]

The investigation and development of PF-610355 were discontinued in 2011,[6] likely for strategic and regulatory reasons.[7]

References

[edit]
  1. ^Diderichsen PM, Cox E, Martin SW, Cleton A, Ribbing J (November 2013)."Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease".British Journal of Clinical Pharmacology.76 (5):752–62.doi:10.1111/bcp.12080.PMC 3853534.PMID 23323609.
  2. ^Cazzola M, Calzetta L, Matera MG (May 2011)."β(2) -adrenoceptor agonists: current and future direction".British Journal of Pharmacology.163 (1):4–17.doi:10.1111/j.1476-5381.2011.01216.x.PMC 3085864.PMID 21232045.
  3. ^"Pfizer Pipeline as of January 27, 2010"(PDF). Pfizer Inc. p. 6. Archived fromthe original(PDF) on 6 September 2015. Retrieved9 April 2016.
  4. ^Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, et al. (September 2010). "Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup".Journal of Medicinal Chemistry.53 (18):6640–52.doi:10.1021/jm1005989.PMID 20804199.
  5. ^Acton QA, ed. (2012-01-09).Issues in Medical Chemistry Edition. ScholarlyEditions.ISBN 978-1-464-96440-4.
  6. ^"AdisInsight: PF 610355". Springer International Publishing AG. Retrieved25 March 2016.
  7. ^Cazzola M, Page CP, Rogliani P, Matera MG (April 2013). "β2-agonist therapy in lung disease".American Journal of Respiratory and Critical Care Medicine.187 (7):690–6.doi:10.1164/rccm.201209-1739PP.PMID 23348973.
α1
Agonists
Antagonists
α2
Agonists
Antagonists
β
Agonists
Antagonists
Adrenergics,inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthinePDE4 inhibitors
Others/unknown
Combination products
Stub icon

Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=PF-610355&oldid=1252516331"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2025 Movatter.jp